FDA Clears IND Application for AXN-2510 for a Ph 1 Trial in Relapsed/Refractory Solid Tumors July 8, 2025
Sanofi to advance Kymera’s next-gen oral IRAK4 degrader KT-485 into clinical testing and will not advance KT-474 July 1, 2025
Hummingbird Bioscience Licenses HMBD-002, Ph 2-Ready Anti-VISTA Monoclonal Antibody, to Percheron Therapeutics July 1, 2025
Revolution Medicines and Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for RAS-Addicted Cancers July 1, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders July 1, 2025
Xcell Biosciences and Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies July 1, 2025
First Patient Dosed in DENALI-1 Ph 1/2 Clinical Study of A2B395 CAR T Cell Therapy for Patients with EGFR-expressing Solid Tumors July 1, 2025
CDR609 Announced as New T-Cell Engager Clinical Candidate Targeting LGR5 in Solid Tumors July 1, 2025
Results from Ph 1 FRAME Study of Avutometinib + Defactinib combo in Solid Tumors, including Low-Grade Serious Ovarian Cancer, published in Nature Medicine July 1, 2025
Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion/Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients Filed July 1, 2025
Orion and Glykos announce the extension of research collaboration and licensing agreement for the development of next-gen ADCs June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel ADC Targeting CDH6 June 24, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel CDH6-targeting ADC June 17, 2025
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology June 17, 2025
Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies June 17, 2025
Results from Ph 1/2 Study of Sacituzumab Tirumotecan (sac-TMT) in Solid Tumors Refractory to Standard Therapies Published in Journal of Hematology & Oncology June 17, 2025
Vividion Therapeutics and Bayer Partnership Aims to Further Strengthen Oncology Pipeline With Solid Tumor Inhibitor June 11, 2025
First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
